Standard Dose Start & Baseline Risk
Starting dose sets baseline nausea risk before any mitigation.
- 0.25 mg: Starting dose (lowest titration tier)
- ~44%: Nausea incidence (fast start) (reported in trials)
- ~15%: Vomiting incidence (without titration)
- Week 1–2: Typical onset (after first dose)
Why nausea spikes early
Delayed gastric emptying triggers early GI discomfort.
Fast titration roughly doubles early nausea incidence.
Dose-dependent risk
Higher starting doses raise nausea and vomiting rates.
Individual variability
Genetics and gut motility shape symptom severity.
Mitigation Strategies Introduced
Four practical tactics blunt the nausea curve.
- +4 wks: Slow titration (per dose step)
- -30%: Meal size (smaller, frequent meals)
- Reduced: Low-fat diet (delayed emptying trigger)
- 20+ min: Eating pace (per meal recommended)
Slow titration
Extending time between dose increases lowers peak nausea.
Slow titration alone can cut peak severity by ~30%.
Smaller, frequent meals
Reduces gastric volume load per sitting.
Low-fat, slow eating
Both reduce delayed gastric emptying discomfort.
Nausea Risk Curve — With vs Without Mitigation
Side-by-side curves show mitigation flattening the spike.
- ~8.4/10: Peak severity (fast, no mitigation) (week 1 spike)
- ~3.5/10: Peak severity (full mitigation) (week 2–3 spike)
- ~4–6 wks: Time to resolution (mitigated) (back to baseline)
- ~8–10 wks: Time to resolution (unmitigated) (slower decline)
Curve shape
Both curves spike then decay; mitigation lowers and shortens the spike.
Combining all four strategies roughly halves peak severity.
Comparative decline rate
Mitigated curves decay faster after their lower peak.
Clinical relevance
Flatter curves improve adherence and reduce discontinuation.
GI Symptom Trend Over Weeks
Tachyphylaxis: GI side effects fade as the body adapts.
- 3–4 wks: Median weeks to improvement (with mitigation)
- ~80%: Patients improving by week 8 (across trials)
- ~5–7%: Discontinuation due to GI effects (overall rate)
- Receptor: Adaptation mechanism (desensitization over time)
Tachyphylaxis
Repeated exposure blunts the GI signaling response.
Symptom trend typically flips from worsening to improving by week 3.
Tracking trend
Weekly symptom scores reveal the decline pattern.
Reinforcing habits
Continued mitigation speeds the adaptation window.
Resolution or Dose Reduction
Most nausea resolves; persistent cases signal dose review.
- ~85–90%: Full resolution rate (within 8–12 weeks)
- ~10–15%: Dose reduction needed (persistent severe cases)
- ~70%: Re-titration success (after slower restart)
- High: Long-term GI tolerance (once maintenance reached)
Expected resolution
Nausea typically resolves within weeks with proper mitigation.
Persistent severe nausea past 8 weeks warrants a dose-reduction discussion.
When to step back
Severe, non-improving symptoms flag a slower re-titration.
Maintenance outlook
Tolerance at the maintenance dose is generally durable.